Analystreport

Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.

Axsome Therapeutics, Inc.  (AXSM) 
Last axsome therapeutics, inc. earnings: 3/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: axsome.com